Churg-Strauss syndrome and leukotriene antagonist use: a respiratory perspective.

Hdl Handle:
http://hdl.handle.net/10147/253861
Title:
Churg-Strauss syndrome and leukotriene antagonist use: a respiratory perspective.
Authors:
Nathani, N; Little, M A; Kunst, H; Wilson, D; Thickett, D R
Affiliation:
Department of Thoracic Medicine, City Hospital, Dudley Road, Birmingham B18 7QH, UK. n.nathani@nhs.net
Citation:
Churg-Strauss syndrome and leukotriene antagonist use: a respiratory perspective. 2008, 63 (10):883-8 Thorax
Publisher:
Thorax
Journal:
Thorax
Issue Date:
Oct-2008
URI:
http://hdl.handle.net/10147/253861
DOI:
10.1136/thx.2007.093955
PubMed ID:
18492740
Abstract:
Churg-Strauss syndrome (CSS) is a rare granulomatous small vessel vasculitis that occurs against a background of longstanding asthma. Leukotriene antagonists (LTAs) are used in the management of asthma and may facilitate a reduction in steroid dosage. Reports of the development of CSS in patients with asthma following the initiation of LTA therapy suggest either a causal association or an unmasking of latent CSS as steroid doses fall. We have undertaken a systematic review to establish whether evidence of a drug induced syndrome exists.
Item Type:
Article
Language:
en
MeSH:
Adolescent; Adult; Aged; Anti-Asthmatic Agents; Antibodies, Antineutrophil Cytoplasmic; Asthma; Child; Churg-Strauss Syndrome; Female; Humans; Leukotriene Antagonists; Male; Middle Aged; Recurrence
ISSN:
1468-3296

Full metadata record

DC FieldValue Language
dc.contributor.authorNathani, Nen_GB
dc.contributor.authorLittle, M Aen_GB
dc.contributor.authorKunst, Hen_GB
dc.contributor.authorWilson, Den_GB
dc.contributor.authorThickett, D Ren_GB
dc.date.accessioned2012-11-29T12:28:49Z-
dc.date.available2012-11-29T12:28:49Z-
dc.date.issued2008-10-
dc.identifier.citationChurg-Strauss syndrome and leukotriene antagonist use: a respiratory perspective. 2008, 63 (10):883-8 Thoraxen_GB
dc.identifier.issn1468-3296-
dc.identifier.pmid18492740-
dc.identifier.doi10.1136/thx.2007.093955-
dc.identifier.urihttp://hdl.handle.net/10147/253861-
dc.description.abstractChurg-Strauss syndrome (CSS) is a rare granulomatous small vessel vasculitis that occurs against a background of longstanding asthma. Leukotriene antagonists (LTAs) are used in the management of asthma and may facilitate a reduction in steroid dosage. Reports of the development of CSS in patients with asthma following the initiation of LTA therapy suggest either a causal association or an unmasking of latent CSS as steroid doses fall. We have undertaken a systematic review to establish whether evidence of a drug induced syndrome exists.en_GB
dc.language.isoenen
dc.publisherThoraxen_GB
dc.rightsArchived with thanks to Thoraxen_GB
dc.subject.meshAdolescent-
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAnti-Asthmatic Agents-
dc.subject.meshAntibodies, Antineutrophil Cytoplasmic-
dc.subject.meshAsthma-
dc.subject.meshChild-
dc.subject.meshChurg-Strauss Syndrome-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshLeukotriene Antagonists-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshRecurrence-
dc.titleChurg-Strauss syndrome and leukotriene antagonist use: a respiratory perspective.en_GB
dc.typeArticleen
dc.contributor.departmentDepartment of Thoracic Medicine, City Hospital, Dudley Road, Birmingham B18 7QH, UK. n.nathani@nhs.neten_GB
dc.identifier.journalThoraxen_GB
dc.description.provinceLeinsteren

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.